ANRONYSEPharmaceutical PreparationsFiscal year ends December 31
Alto Neuroscience, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$22.82+0.88 (+4.01%)
Close on Oct 19, 2026
- Market cap
- $976.99M
- P/E (TTM)
- –
- Dividend yield
- –
SEC filings
40 of Alto Neuroscience's most recent filings on SEC EDGAR
| Document | Form | Period | Filed | Source |
|---|---|---|---|---|
| Current report | 8-K | Aug 26, 2026 | Aug 27, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Jun 30, 2026 | Aug 12, 2026 | SEC EDGAR |
| Current report | 8-K | Aug 12, 2026 | Aug 12, 2026 | SEC EDGAR |
| Current report | 8-K | Jul 13, 2026 | Jul 14, 2026 | SEC EDGAR |
| Current report | 8-K | Jul 13, 2026 | Jul 13, 2026 | SEC EDGAR |
| Current report | 8-K | May 27, 2026 | May 28, 2026 | SEC EDGAR |
| Current report | 8-K | May 12, 2026 | May 13, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Mar 31, 2026 | May 13, 2026 | SEC EDGAR |
| Current report | 8-K | May 13, 2026 | May 13, 2026 | SEC EDGAR |
| Current report | 8-K | Apr 1, 2026 | Apr 1, 2026 | SEC EDGAR |
| Proxy statement | DEF 14A | May 12, 2026 | Mar 26, 2026 | SEC EDGAR |
| Annual report | 10-K | Dec 31, 2025 | Mar 16, 2026 | SEC EDGAR |
| Current report | 8-K | Mar 16, 2026 | Mar 16, 2026 | SEC EDGAR |
| Current report | 8-K | Mar 16, 2026 | Mar 16, 2026 | SEC EDGAR |
| Quarterly report | 10-Q | Sep 30, 2025 | Nov 12, 2025 | SEC EDGAR |
| Current report | 8-K | Nov 12, 2025 | Nov 12, 2025 | SEC EDGAR |
| Current report | 8-K | Oct 19, 2025 | Oct 20, 2025 | SEC EDGAR |
| Quarterly report | 10-Q | Jun 30, 2025 | Aug 13, 2025 | SEC EDGAR |
| Current report | 8-K | Aug 12, 2025 | Aug 13, 2025 | SEC EDGAR |
| Current report | 8-K | Jul 3, 2025 | Jul 8, 2025 | SEC EDGAR |
| Current report | 8-K | Jun 26, 2025 | Jun 26, 2025 | SEC EDGAR |
| Current report | 8-K | May 31, 2025 | Jun 3, 2025 | SEC EDGAR |
| Quarterly report | 10-Q | Mar 31, 2025 | May 14, 2025 | SEC EDGAR |
| Current report | 8-K | May 13, 2025 | May 14, 2025 | SEC EDGAR |
| Proxy statement | DEF 14A | May 13, 2025 | Apr 1, 2025 | SEC EDGAR |
| Annual report | 10-K | Dec 31, 2024 | Mar 20, 2025 | SEC EDGAR |
| Current report | 8-K | Mar 17, 2025 | Mar 20, 2025 | SEC EDGAR |
| Current report | 8-K | Feb 12, 2025 | Feb 12, 2025 | SEC EDGAR |
| Current report | 8-K | Feb 3, 2025 | Feb 3, 2025 | SEC EDGAR |
| Current report | 8-K | Jan 13, 2025 | Jan 16, 2025 | SEC EDGAR |
| Quarterly report | 10-Q | Sep 30, 2024 | Nov 12, 2024 | SEC EDGAR |
| Current report | 8-K | Nov 12, 2024 | Nov 12, 2024 | SEC EDGAR |
| Current report | 8-K | Oct 22, 2024 | Oct 22, 2024 | SEC EDGAR |
| Quarterly report | 10-Q | Jun 30, 2024 | Aug 13, 2024 | SEC EDGAR |
| Current report | 8-K | Aug 13, 2024 | Aug 13, 2024 | SEC EDGAR |
| Current report | 8-K | Jul 24, 2024 | Jul 29, 2024 | SEC EDGAR |
| Current report | 8-K | May 21, 2024 | May 21, 2024 | SEC EDGAR |
| Quarterly report | 10-Q | Mar 31, 2024 | May 14, 2024 | SEC EDGAR |
| Current report | 8-K | May 14, 2024 | May 14, 2024 | SEC EDGAR |
| Annual report | 10-K | Dec 31, 2023 | Mar 21, 2024 | SEC EDGAR |